呼吸道菌群失调在医院获得性肺炎中的病理生理作用
本文综述医院获得性肺炎的现有数据与未解问题,讨论住院患者呼吸道微生物组和黏膜免疫的改变,并探索患者分层以实施个体化治疗的潜在方法。肺部曾被视为无菌器官,但非培养技术显示健康肺存在多样动态的细菌生态系统,理解菌群失调与黏膜免疫改变有望开发靶向宿主导向免疫治疗,以减少无效治疗、改善预后并应对耐药细菌的全球威胁。
要点
- 非培养技术证实健康肺存在多样动态细菌生态系统,改变了对呼吸道病理生理的理解。
- 医院获得性肺炎全球发病率仍高,治疗常无效,需关注呼吸道菌群失调与黏膜免疫改变。
- 理解危重症患者菌群失调与黏膜免疫改变,有望开发靶向宿主导向免疫治疗。
核心结论
- 理解呼吸道微生物组失调和黏膜免疫改变,有望开发靶向宿主导向免疫治疗,减少无效治疗、改善预后并应对耐药细菌威胁。
研究设计与样本
- 本文为综述,回顾医院获得性肺炎的现有数据与未解问题,讨论呼吸道微生物组和黏膜免疫改变,并探索患者分层方法。
主要发现
- 医院获得性肺炎是全球发病和死亡的主要原因,发病率仍高且治疗常无效。
- 非培养技术显示健康肺存在多样动态的细菌生态系统,改变了此前肺为无菌器官的认知。
临床怎么用
- 临床应关注医院获得性肺炎患者的呼吸道菌群失调与黏膜免疫改变,为个体化治疗和宿主导向免疫治疗提供思路。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hospital-acquired pneumonia is a major cause of morbidity and mortality. The incidence of hospital-acquired pneumonia remains high globally and treatment can often be ineffective. Here, we review the available data and unanswered questions surrounding hospital-acquired pneumonia, discuss alterations of the respiratory microbiome and of the mucosal immunity in patients admitted to hospital, and explore potential approaches to stratify patients for tailored treatments. The lungs have been considered a sterile organ for decades because microbiological culture techniques had shown negative results. Culture-independent techniques have shown that healthy lungs harbour a diverse and dynamic ecosystem of bacteria, changing our comprehension of respiratory physiopathology. Understanding dysbiosis of the respiratory microbiome and altered mucosal immunity in patients with critical illness holds great promise to develop targeted host-directed immunotherapy to reduce ineffective treatment, to improve patient outcomes, and to tackle the global threat of resistant bacteria that cause these infections.
引用
- Roquilly A, Torres A, Villadangos JA, et al. Pathophysiological role of respiratory dysbiosis in hospital-acquired pneumonia. Lancet Respir Med. 2019. PMID: 31182406. doi:10.1016/S2213-2600(19)30140-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。